Genelux (NASDAQ:GNLX) Insider Sells $26,628.25 in Stock

Genelux Corporation (NASDAQ:GNLX) insider Yong Yu sold 9,683 shares of the firm’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $2.75, for a total transaction of $26,628.25. Following the transaction, the insider directly owned 258,688 shares of the company’s stock, valued at $711,392. The trade was a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Yong Yu also recently made the following trade(s):

• On Tuesday, August 4th, Yong Yu sold 653 shares of Genelux stock. The shares were sold at an average price of $2.94, for a total transaction of $1,919.82.

Genelux Stock Down 3.2%

Shares of GNLX stock opened at $2.44 on Friday. The company’s fifty day simple moving average is $2.81 and its two-hundred day simple moving average is $2.78. Genelux Corporation has a 52 week low of $2.29 and a 52 week high of $8.53. The stock has a market cap of $110.39 million, a P/E ratio of -2.84 and a beta of 0.57.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). On average, analysts anticipate that Genelux Corporation will post -0.81 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Wall Street Zen raised Genelux from a “strong sell” rating to a “sell” rating in a research note on Sunday, August 23rd. Benchmark reiterated a “speculative buy” rating on shares of Genelux in a research report on Tuesday, August 18th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a report on Friday, July 17th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Genelux has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Institutional Trading of Genelux

Several hedge funds have recently made changes to their positions in GNLX. Jefferies Financial Group Inc. bought a new position in shares of Genelux in the 4th quarter valued at about $48,000. GSA Capital Partners LLP bought a new stake in Genelux during the second quarter worth approximately $35,000. Squarepoint Ops LLC purchased a new stake in Genelux during the fourth quarter valued at approximately $52,000. Balyasny Asset Management L.P. purchased a new stake in Genelux during the fourth quarter valued at approximately $94,000. Finally, Align Financial LLC bought a new stake in shares of Genelux in the 4th quarter valued at approximately $123,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.